The Food and Drug Administration on Monday approved the drug aducanumab as a treatment for Alzheimer’s disease, the first ever intended to slow the progression of the incurable dementia. The go-ahead marks a rare case in which the FDA went against the recommendations of the outside panel it solicited for advice, who…
via Gizmodo